BOSTON, Feb. 01, 2024 (GLOBE NEWSWIRE) — Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced that Sekar Kathiresan, M.D., co-founder and chief executive officer, will participate in a fireside chat at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference on Thursday, February 8, 2024 at 11:30 a.m. ET in New York.
A live webcast will be available in the investor section of the company’s website at www.vervetx.com. The webcast will be archived for 30 days following the presentation.
About Verve Therapeutics
Verve Therapeutics, Inc. is a clinical-stage genetic medicines company pioneering a new approach to the care of cardiovascular disease, potentially transforming treatment from chronic management to single-course gene editing medicines. The company’s initial three programs – VERVE-101, VERVE-102, and VERVE-201 – target genes that have been extensively validated as pharmacologic targets for lowering low-density lipoprotein cholesterol (“LDL-C”), a root cause of cardiovascular disease, in order to durably reduce blood LDL-C levels.
Investor Contact
Jen Robinson
Verve Therapeutics, Inc.
[email protected]
Media Contact
Ashlea Kosikowski
1AB
[email protected]
Bay Street News
